U.O. Malattie Infettive, AO Ospedale di Circolo di Busto Arsizio, Ple Solaro 3, 21052 Busto Arsizio, Italy.
Future Oncol. 2013 Aug;9(8):1231-7. doi: 10.2217/fon.13.86.
Sorafenib (SO) was the first targeted agent to produce significant improvements in overall survival in patients with advanced hepatocellular carcinoma (HCC). We report the case of a cirrhotic patient with chronic hepatitis C virus infection; locally advanced, unresectable, multinodular HCC, and portal vein tumor thrombosis, who achieved complete tumor regression following SO treatment. The patient was treated with SO 400 mg twice daily, which was subsequently reduced to 200 mg twice daily due to the occurrence of hand-foot skin reaction. The patient also received the following concomitant medications: Synchro-Levels(®) (Alphrema, Varese, Italy), silymarin and vitamin E. Long-term treatment with reduced SO dosage and Synchro-Levels resulted in a sustained radiological and clinical response with normalization of α-fetoprotein levels. Observed side effects were mostly low grade and manageable following dose adjustments. After 44 months of treatment the patient was in good physical condition, which suggests that a complete response with long-term SO is achievable in patients with locally advanced HCC.
索拉非尼（SO）是首个在晚期肝细胞癌（HCC）患者的总生存期方面产生显著改善的靶向药物。我们报告了一例患有慢性丙型肝炎病毒感染的肝硬化患者的病例；局部晚期、不可切除、多结节 HCC 和门静脉癌栓，在 SO 治疗后实现了完全肿瘤消退。该患者接受 SO 400 mg 每日两次治疗，随后由于出现手足皮肤反应而减少至 200 mg 每日两次。该患者还接受了以下伴随药物治疗：Synchro-Levels®（Alphrema，瓦雷泽，意大利）、水飞蓟素和维生素 E。长期使用降低剂量的 SO 和 Synchro-Levels 导致持续的影像学和临床反应，甲胎蛋白水平正常化。观察到的副作用在调整剂量后大多为低级别且可管理。经过 44 个月的治疗，患者身体状况良好，这表明局部晚期 HCC 患者可以实现完全缓解和长期使用 SO。
